All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The QUAZAR AML-001 trial has been extensively covered on our hub, with key results demonstrating that maintenance with oral azacitidine (AZA) improves overall survival (OS) and relapse-free survival (RFS) when compared with placebo in elderly patients with acute myeloid leukemia (AML) in first complete remission. At the European Hematology Association (EHA) 2022 Congress, Andrew Wei presented updated results for long-term survival with oral azacitidine from this trial,1 which we are pleased to summarize here.
In summary, updated results from the QUAZAR AML-001 trial demonstrated that treatment with oral azacitidine led to improved LTS outcomes compared with placebo (34.9% vs 24.4%). Oral azacitidine was also significantly associated with improved LTS in a multivariable analysis.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox